Resources

Poster: Accelerating Development and Manufacturing Platform for Viral Vector

Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. In this poster, we will discuss our recent technical advancement on efficient viral vector manufacturing process development. From cell line development, suspension culture of HEK293 cells, media optimization and purification process, a series of progress were implemented to advance our …Read More >

Resource Type: Poster
Resource Topic: Analytical Development Clinical & Commercial Manufacturing Process Development

VIEW

Roundtable Discussion: Cell and Gene Therapies — Keep the Work In-House, or Use a Third Party?

During BIO 2019, BioProcess International hosted a roundtable discussion on “Cell and Gene Therapies – Keep the work in-house or use a third party” at BPI Theater. It was moderated by BioProcess Insider editor Dan Stanton with industry leaders that included Felix Hsu, Senior Vice President and Global Head of WuXi Advanced Therapies, Celonic Group, …Read More >

Resource Type: Video
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Multibillion-Dollar Race for Gene Therapy Manufacturing

“Gene therapy, a promising therapeutic approach that corrects disease-causing genetic errors, has spurred an arms race among the world’s largest pharmaceutical companies. Novartis (NYSE: NVS) announced the acquisition of AxeVis for a whopping $8.7 billion in 2018. Roche (NASDAQOTH: RHHBY) agreed to acquire gene therapy developer Spark Therapeutics for $4.8 billion in early 2019. One week …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW

NextUp: WuXi AppTec Is Speeding Up Drug Development Worldwide

NextUp: WuXi AppTec Is Speeding Up Drug Development Worldwide The Chinese pharma company, with its deep South Philadelphia Navy Yard presence, is globally recognized for building an innovative platform that shortens drug discovery and research and development time. By Queen Muse· 7/1/2019, 8:00 a.m. “NextUp” is a weekly NextHealth PHL feature that highlights the local …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Contract Pharma Interview with SVP and global head of advanced therapies talks about cell and gene therapy market trends

WuXi AppTec’s Felix Hsu on ‘Make vs Buy’ Decisions At BIO 2019, Contract Pharma had a chance to talk with WuXi AppTec’s Felix Hsu, SVP and Global Head of Advanced Therapies, about “Make vs Buy” decisions, as well as cell and gene therapy market trends.

Resource Type: Video
Resource Topic: Clinical & Commercial Manufacturing

VIEW